FIELD: biotechnology.
SUBSTANCE: new anti-OX40 antibodies, which specifically bind and activate OX40, a nucleic acid molecule encoding these antibodies, an expression vector containing such a nucleic acid molecule, an eucaryotic host cell for producing anti-OX40 antibodies that is transformed by the expression vector, and a method for producing anti-OX40 antibodies are presented.
EFFECT: group of inventions is used for effective treatment of malignant tumors of various etiologies.
9 cl, 8 dwg, 16 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MONOSPECIFIC AND BISPECIFIC PROTEINS WITH IMMUNE CHECKPOINT REGULATION FOR CANCER TREATMENT | 2018 |
|
RU2793167C2 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732591C2 |
| BISPECIFIC 2+1 ANTIBODIES | 2018 |
|
RU2797305C2 |
| IMPROVED SYNTHETIC T-CELL RECEPTOR AND ANTIGEN RECEPTOR | 2021 |
|
RU2820497C1 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USE | 2016 |
|
RU2817838C2 |
| POLYVALENT AND POLYSPECIFIC OX40-BINDING FUSED PROTEINS | 2017 |
|
RU2773052C2 |
| BISPECIFIC ANTIBODIES SPECIFIC RELATIVELY TO COSTIMULATORY TNF-RECEPTOR | 2016 |
|
RU2761115C1 |
| ANTIBODY MOLECULES THAT BIND CD137 AND OX40 | 2019 |
|
RU2817602C2 |
| COMPOSITIONS AND METHODS FOR CONNECTING EXTRACELLULAR DOMAINS OF TYPE I AND TYPE II AS HETEROLOGOUS CHIMERIC PROTEINS | 2016 |
|
RU2766200C1 |
| ANTI-PCSK9 ANTIBODY, ITS ANTIGEN-BINDING DOMAIN AND MEDICAL APPLICATION THEREOF | 2016 |
|
RU2739208C2 |
